PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Obstacles”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,063 records · Page 59Linked to original sources
PubMed2001

Competition no obstacle in a new cancer project created by consortium.

Cancer hospitals always are quick to explain that they are different, often pointing to their special commitment to their patients and ability to deal with end-of-life issues. But those differences are rarely accounted for in the benchmarking data they use. The facilities have a keen sense of competition and have, until recently, been unwilling to come together for benchmarking purposes. But all that changed in 1997 when the Joint Commission on Accreditation of Healthcare Organizations started talking about ORYX. Cancer hospital executives knew from experience that comparing data with noncancer hospitals wouldn't be useful, so a group of them came together and created a National Cancer Database initiative that would allow for subcomparisons within the ORYX system.

Benchmarking↗
PubMed2001

[Research results should be freely accessible!-- Case reports demonstrate obstacles to contact with drug industry].

Recommendations on the use of medical technologies should be based on best available evidence. Publication bias due to delayed publication or non-publication of negative studies leads to inflated effect sizes in systematic reviews. We carried out a health technology assessment on prevention and treatment of venous thromboembolism, and in order to minimize publication bias asked the six pharmaceutical companies with antithrombotic drugs registered in Sweden to supply us with results from unpublished clinical trials. The answers were returned after 4 to 60 weeks, and with only one exception, after multiple reminders by telephone, fax and e-mail. No relevant unpublished studies were reported to us although we were made aware of two published studies that our literature search had not identified. One company did not mention a large negative unpublished clinical trial with their drug which has remained unpublished due to conflict between the company and the steering committee. We conclude that the companies did not contribute much and that the process was very time consuming with little result. As non-publication of trial results is unethical, we propose agreements between industry and researchers that all studies be prospectively registered and made publicly available.

Clinical Trials as Topic↗